[go: up one dir, main page]

PE20020382A1 - Derivados de acido heteroarilalcanoico como antagonistas de la integrina - Google Patents

Derivados de acido heteroarilalcanoico como antagonistas de la integrina

Info

Publication number
PE20020382A1
PE20020382A1 PE2001000576A PE2001000576A PE20020382A1 PE 20020382 A1 PE20020382 A1 PE 20020382A1 PE 2001000576 A PE2001000576 A PE 2001000576A PE 2001000576 A PE2001000576 A PE 2001000576A PE 20020382 A1 PE20020382 A1 PE 20020382A1
Authority
PE
Peru
Prior art keywords
methyl
alkyl
derivatives
ilamine
oxadiazol
Prior art date
Application number
PE2001000576A
Other languages
English (en)
Inventor
Nizal Samuel Chandrakumar
Barbara B Chen
Michael Clare
Balekudru Devadas
Alan F Gasiecki
Mark Russell
Hwang-Fun Lu
Thomas D Penning
Nagarajan Srinivasan Raj Raj
Thomas Rogers
Ish Kumar Khanna
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of PE20020382A1 publication Critical patent/PE20020382A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A DERIVADOS DE ACIDO HETEROARILALCANOICO DE FORMULA I DONDE A ES UN ANILLO MONOCICLICO DE 4-8 MIEMBROS O UN ANILLO BICICLICO DE 7-12 MIEMBROS QUE CONTIENE 1 A 4 HETEROATOMOS SELECCIONADOS DE O, N, S OPCIONALMENTE SATURADO O INSATURADO CON ALQUILO, HALOALQUILO, ARILO HETEROARILO, CON LA CONDICION DE QUE CUANDO Y4 EN LA FORMULA I ES H, EL ANILLO A PUEDE NO SER UN OXAZOL CON UNA CADENA LATERAL QUE CONTIENEN X-Y CONECTADA EL CARBONO 2; A1 ES UN HETEROCICLO MONOCICLICO DE 5-9 MIEMBROS, POLICICLICO DE 7-14 MIEMBROS DE FORMULA a QUE CONTIENE POR LO MENOS UN ATOMO DE N DONDE RK ES OH, ALQUILO, ALCOXI, ENTRE OTROS; R2 ES H, ALQUILO, ARILO, OH, ALCOXI, ENTRE OTROS; R2 JUNTO A R7 FORMA UN HETEROCICLO QUE CONTIENE DINITROGENO DE 4-12 MIEMBROS CON ALQUILO, TIOALQUILO, ALQUILAMINO, OH, CETO, ENTRE OTROS; Y2 ES ALQUILO, CICLOALQUILO, BICICLOALQUILO, ENTRE OTROS; Z1 ES CH2, O, NH, CO, ENTRE OTROS; Z2 ES UN ENLAZANTE DE 2-5 CARBONOS; X ES S, SO2, CO, ENTRE OTROS; Y ES CO, SO2, ENTRE OTROS; Y3 E Y4 SON H, ALQUILO, HALOALQUILO, ENTRE OTROS; Y5 ES C; Rb ES OH. SON COMPUESTOS PREFERIDOS ACIDO 3-METIL-4-(3-{3-[(PIRIDIN-2-ILAMINO)METIL]FENIL-1,2,4-OXADIAZOL-5-IL-BUTANOICO, ACIDO 3-METIL-4-(3-{4-[(PIRIDIN-2-ILAMINO)METIL]FENIL-1,2,4-OXADIAZOL-5-IL-BUTANOICO, ACIDO [1-({3-[4-(PIRIDIN-2-ILAMINO)BUTIL]-1,2,4-OXADIAZOL-5-IL}METIL)CICLOPENTIL]-ACETICO, ENTRE OTROS. LOS DERIVADOS DE ACIDO HETEROARILALCANOICO SON ANTAGONISTAS DE LA INTEGRINA E INHIBEN LA ANGIOGENES, METASTASIS TUMORAL
PE2001000576A 2000-06-15 2001-06-15 Derivados de acido heteroarilalcanoico como antagonistas de la integrina PE20020382A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21178200P 2000-06-15 2000-06-15
US21178100P 2000-06-15 2000-06-15

Publications (1)

Publication Number Publication Date
PE20020382A1 true PE20020382A1 (es) 2002-05-10

Family

ID=26906455

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000576A PE20020382A1 (es) 2000-06-15 2001-06-15 Derivados de acido heteroarilalcanoico como antagonistas de la integrina

Country Status (7)

Country Link
US (2) US7119098B2 (es)
EP (1) EP1289983A2 (es)
JP (1) JP2004511434A (es)
AR (1) AR031109A1 (es)
AU (1) AU2001269876A1 (es)
PE (1) PE20020382A1 (es)
WO (1) WO2001096334A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004511434A (ja) * 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
DK1371646T3 (da) 2001-03-19 2010-07-05 Dainippon Sumitomo Pharma Co Arylsubstitueret alicyklisk forbindelse og medicinsk præparat omfattende det samme
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
US20050004200A1 (en) * 2002-12-20 2005-01-06 Pharmacia Corporation Pyrazole compounds as integrin receptor antagonists derivatives
JP2006516144A (ja) * 2002-12-20 2006-06-22 ファルマシア・コーポレーション インテグリン受容体アンタゴニスト誘導体としてのチアゾール化合物
JP2006518333A (ja) * 2002-12-20 2006-08-10 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
US7351711B2 (en) 2003-07-31 2008-04-01 Janssen Pharmaceutical, N.V. Tricyclic indanyls as integrin inhibitors
US20080306116A1 (en) * 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
TW201010700A (en) * 2008-08-25 2010-03-16 Piramal Lifesciences Ltd Diacylglycerol acyltransferase inhibitors
JP5719835B2 (ja) * 2009-04-27 2015-05-20 ダウ アグロサイエンシィズ エルエルシー 殺虫性ピリジン化合物
JP5791150B2 (ja) * 2009-12-15 2015-10-07 塩野義製薬株式会社 血管内皮リパーゼ阻害活性を有するオキサジアゾール誘導体
ES2742195T3 (es) 2010-03-12 2020-02-13 Omeros Corp Inhibidores de PDE10 y composiciones y métodos relacionados
CN104640857B (zh) 2012-07-18 2017-07-04 圣路易斯大学 作为整合素拮抗剂的β氨基酸衍生物
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
GB201417018D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2016250843A1 (en) 2015-04-24 2017-10-12 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
KR20180107121A (ko) 2015-12-30 2018-10-01 세인트 루이스 유니버시티 팬 인테그린 길항제로서의 메타-아자사이클릭 아미노 벤조산 유도체
GB201604680D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
US10851098B2 (en) * 2016-11-08 2020-12-01 Bristol-Myers Squibb Company Azole amides and amines as alpha v integrin inhibitors
BR112019012515A2 (pt) * 2016-12-29 2019-11-19 Saint Louis University antagonistas de integrina
AU2018227417B2 (en) 2017-02-28 2021-12-23 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
TW201835078A (zh) 2017-02-28 2018-10-01 美商萊築理公司 αvβ6整合蛋白之抑制劑
EP3630769B1 (en) 2017-05-22 2025-07-02 Topadur Pharma AG Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
HUE065887T2 (hu) * 2018-03-07 2024-06-28 Pliant Therapeutics Inc Aminosav vegyületek és alkalmazási eljárások
EP4086254B1 (en) 2018-08-29 2024-12-18 Morphic Therapeutic, Inc. Integrin inhibitors
CN109369530B (zh) * 2018-11-15 2022-03-04 河北三川化工有限公司 一种2,4-二氧-3-氮杂-螺[5,5]十一烷-1,5-二腈的制备方法
EP4054608A4 (en) * 2019-11-06 2024-02-21 Albert Einstein College of Medicine LOW MOLECULAR PROSTAGLADINE TRANSPORT INHIBITORS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9023289D0 (en) 1990-10-25 1990-12-05 Ici Plc Herbicides
JP3322878B2 (ja) 1992-10-14 2002-09-09 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
EP0894084B1 (en) 1996-03-29 2002-06-26 G.D. Searle & Co. Cinnamic acid derivatives and their use as integrin antagonists
AU2337097A (en) 1996-03-29 1997-10-22 G.D. Searle & Co. Meta-substituted phenylene derivatives and their use as alphavbeta3 integrin antagonists or inhibitors
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
JP2001524481A (ja) 1997-11-26 2001-12-04 デュポン ファーマシューティカルズ カンパニー αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類
WO1999030709A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
JP2002508326A (ja) 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
CZ2001447A3 (cs) 1998-08-07 2001-08-15 Smithkline Beecham Corporation Antagonista receptoru vitronektinu
SK17442001A3 (sk) 1999-06-02 2002-03-05 Merck & Co., Inc. Deriváty kyseliny nonánovej, farmaceutický prostriedok s ich obsahom a ich použitie
AU7743400A (en) 1999-10-04 2001-05-10 Merck & Co., Inc. Integrin receptor antagonists
JP2004511434A (ja) 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸

Also Published As

Publication number Publication date
US20040092497A1 (en) 2004-05-13
US7119098B2 (en) 2006-10-10
EP1289983A2 (en) 2003-03-12
JP2004511434A (ja) 2004-04-15
US20020133023A1 (en) 2002-09-19
US6933304B2 (en) 2005-08-23
AU2001269876A1 (en) 2001-12-24
WO2001096334A3 (en) 2002-09-12
AR031109A1 (es) 2003-09-10
WO2001096334A2 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
PE20020382A1 (es) Derivados de acido heteroarilalcanoico como antagonistas de la integrina
ATE432007T1 (de) Fungizide ternäre wirkstoffkombinationen
EA200600315A1 (ru) Пиримидиновые соединения, их применение в качестве a-селективных антагонистов и способ их получения
PE20050147A1 (es) Derivados de pirimidina, piridina y tiazol como inhibidores de fosfatidilinositol 3-quinasa
NO20061107L (no) CRF-antagonister og heterobrcykliske forbindelser
CO5251452A1 (es) Oxazoles sustituidos y derivados de tiazoles como activadores de alfa hppar
PE20050018A1 (es) Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b)
TR199701218T2 (xx) Benzimidazol bile�ikleri ve bunlar� i�eren farmakolojik bile�imler.
RU2006147267A (ru) Конденсированное гетероциклическое соединение
NZ602099A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
PE20010671A1 (es) Indolinonas sustituidas en posicion 6 como inhibidores de tirosina-quinasas
EA200600925A1 (ru) Производные триазола в качестве антагонистов вазопрессина
PE20001483A1 (es) Acidos oxamicos y derivados como ligandos de receptores tiroideos
ES2571327T3 (es) Composiciones plaguicidas
PE20090897A1 (es) Compuestos de biciclolactama sustituida como inhibidores de la enzima dgat-1
NZ594597A (en) Substituted piperidines as ccr3 antagonists
RU2007143966A (ru) Конденсированные гетероциклические соединения
ATE316967T1 (de) Zyklische amidderivate die cathepsin k hemmen
ES2178451T3 (es) Derivados de benzoxadiazoles, benzotiadiazoles, benzotriazoles y quinoxalinas.
NO20064175L (no) Heterosyklisk forbindelse
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1
IN2012DN02871A (es)
RU2342363C2 (ru) Бензоилпиперидиновые соединения
DE60011226D1 (de) Substituierte 1-(piperidin-4-yl)-3-(aryl)-isothioharnstoffe , ihre herstellung und therapeutische verwendung
AR053409A1 (es) 4-(2,4-dicloro-5-metoxifenil)amino-6-metoxi-7-((5-(amino-sustituido)metil)-3-furil)-3-quinolincarbonitrilos como inhibidores de quinasa. procesos de obtencion y composiciones farmaceuticas.

Legal Events

Date Code Title Description
FD Application declared void or lapsed